4D Molecular Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
4D Molecular Therapeutics, Inc. carries a market capitalization of 594.64M, placing it among publicly traded companies globally. Its enterprise value stands at 188.61M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 594.64M |
| Enterprise Value | 188.61M |
Share Statistics
4D Molecular Therapeutics, Inc. currently has 52.27M shares outstanding.
| Shares Outstanding | 52.27M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 6.33, and the price-to-book ratio stands at -0.71.
| PE Ratio | N/A |
| PS Ratio | 6.33 |
| PB Ratio | -0.71 |
| P/TBV Ratio | 1.24 |
| P/FCF Ratio | -4.31 |
| P/OCF Ratio | -4.32 |
Enterprise Valuation
| EV / Sales | 2.14 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
4D Molecular Therapeutics, Inc. maintains a current ratio of 9.34, meaning it holds 9.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 9.34 |
| Quick Ratio | 9.01 |
| Debt / Equity | 4.54 |
| Debt / EBITDA | -0.12 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -31.28 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
4D Molecular Therapeutics, Inc.'s stock has gained approximately 168.2783% over the past 52 weeks. The 50-day moving average sits at 10.36, while the 200-day moving average is 9.71.
| Beta (5Y) | N/A |
| 52-Week Price Change | 168.2783% |
| 50-Day Moving Average | 10.36 |
| 200-Day Moving Average | 9.71 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, 4D Molecular Therapeutics, Inc. generated 88.24M in revenue and converted that into -160.90M in net income, yielding earnings per share of -2.68. EBITDA reached -171.62M, while operating income came in at -179.55M.
| Revenue | 88.24M |
| Gross Profit | N/A |
| Operating Income | -179.55M |
| Pretax Income | -160.90M |
| Net Income | -160.90M |
| EBITDA | -171.62M |
| EBIT | -179.55M |
| Earnings Per Share (EPS) | -2.68 |
Balance Sheet
4D Molecular Therapeutics, Inc. holds 390.89M in cash and equivalents against 20.54M in total debt, resulting in a net debt position of -72.49M. Total book value stands at -785.06M, with working capital of 361.96M providing operational flexibility.
| Cash & Cash Equivalents | 390.89M |
| Total Debt | 20.54M |
| Net Debt | -72.49M |
| Equity (Book Value) | -785.06M |
| Book Value Per Share | -13.08 |
| Working Capital | 361.96M |
Cash Flow
4D Molecular Therapeutics, Inc. produced -129.45M in operating cash flow over the past twelve months. After subtracting 95,000.00 in capital expenditures, free cash flow totaled -129.35M - equivalent to -2.15 per share.
| Operating Cash Flow | -129.45M |
| Capital Expenditures | 95,000.00 |
| Free Cash Flow | -129.35M |
| FCF Per Share | -2.15 |
Margins
4D Molecular Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -203.47 and net profit margin of -182.34 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -203.47 |
| Pretax Margin | -182.34 |
| Profit Margin | -182.34 |
| EBITDA Margin | -194.49 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -22.26 |
| FCF Yield | -23.18 |
Scores
4D Molecular Therapeutics, Inc. posts an Altman Z-Score of 3.21, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.21 |